-
41.
公开(公告)号:US20110152220A1
公开(公告)日:2011-06-23
申请号:US12935651
申请日:2009-03-30
IPC分类号: A61K31/663 , A61K31/198 , A61K31/4375 , A61K31/513 , A61K31/36 , A61K31/472 , C07C229/36 , C07D455/03 , C07D317/60 , C07D217/20 , C07D211/34 , G01N33/53 , C07D221/18 , A61P19/10 , A61P35/04 , A61P19/08 , G01N27/26
CPC分类号: A61K31/505 , A61K31/357 , A61K31/513 , A61K45/06 , G01N33/942 , G01N2800/108 , G01N2800/50 , A61K2300/00
摘要: The present invention provides methods and therapeutic agents for lowering or increasing serum serotonin levels in a patient in order to increase or decrease bone mass, respectively. In preferred embodiments, the patient is known to have, or to be at risk for, a low bone mass disease such as osteoporosis and the agents are TPH1 inhibitors or serotonin receptor antagonists.
摘要翻译: 本发明提供用于降低或增加患者血清5-羟色胺水平的方法和治疗剂,以分别增加或减少骨质量。 在优选的实施方案中,已知患者具有或具有低骨量疾病如骨质疏松症的风险,并且该药物是TPH1抑制剂或血清素受体拮抗剂。
-
公开(公告)号:US20110118353A1
公开(公告)日:2011-05-19
申请号:US12740716
申请日:2008-11-04
IPC分类号: A61K31/198 , C07C229/36 , A61P5/26 , A61P5/30 , A61P5/24 , A61P15/00
CPC分类号: A61K31/198
摘要: The present invention relates to a glycine transporter-1 inhibitor having the formula (I) wherein X is 1-3 substituents selected from H, halogen, methyl, methoxy, trifluoromethyl and trifluoromethoxy and Y is 1-3 substituents selected from H, methyl and halogen or a pharmaceutically acceptable salt thereof for use in a treatment in humans to suppress the level of one or more hormone selected from luteinizing hormone, follicle-stimulating hormone, estradiol and testosterone. The present invention further relates to such a glycine transporter-1 inhibitor as part of a contraceptive regimen or as a treatment for hypersexuality.
摘要翻译: 本发明涉及具有式(I)的甘氨酸转运蛋白-1抑制剂,其中X是1-3个选自H,卤素,甲基,甲氧基,三氟甲基和三氟甲氧基的取代基,Y是1-3个选自H,甲基和 卤素或其药学上可接受的盐,用于人类的治疗以抑制选自黄体生成激素,促卵泡激素,雌二醇和睾酮的一种或多种激素的水平。 本发明还涉及作为避孕方案的一部分的甘氨酸转运蛋白-1抑制剂或作为超嗜性的治疗剂。
-
43.
公开(公告)号:US20110020324A1
公开(公告)日:2011-01-27
申请号:US12879158
申请日:2010-09-10
申请人: Shinji NAKADE , Hirotaka Mizuno , Takeji Ono , Masashi Minami , Hiroshi Saga , Hiroshi Hagiya , Takaki Komiya , Hiromu Habashita , Haruto Kurata , Kazuhiro Ohtsuki , Kensuke Kusumi
发明人: Shinji NAKADE , Hirotaka Mizuno , Takeji Ono , Masashi Minami , Hiroshi Saga , Hiroshi Hagiya , Takaki Komiya , Hiromu Habashita , Haruto Kurata , Kazuhiro Ohtsuki , Kensuke Kusumi
IPC分类号: A61K31/197 , C07C229/36 , A61K31/198 , C07C229/34 , C07D207/16 , A61K31/401 , A61K31/40 , C07D211/60 , A61K31/445 , C07D211/62 , C07D205/04 , A61K31/397 , A61K31/24 , A61P37/06 , A61P37/08 , A61K31/56 , A61K39/395
CPC分类号: C07C229/36 , A61K31/197 , A61K31/198 , A61K31/397 , A61K31/401 , A61K31/44 , A61K31/445 , A61K45/06 , C07C229/14 , C07C229/22 , C07C229/34 , C07C233/47 , C07C255/16 , C07C255/41 , C07C271/22 , C07C323/12 , C07D205/04 , C07D207/16 , C07D211/62 , C07D211/70 , C07D217/04
摘要: A compound having an ability to bind to an S1P receptor (particularly EDG-6, preferably EDG-1 and EDG-6), for example, the compound represented by formula (I) of the present invention, a salt thereof, a solvate thereof or a prodrug thereof is useful for prevention and/or treatment of rejection of transplantation, graft-versus-host disease, autoimmune disease, allergic disease and the like. wherein ring A is a cyclic group; ring B is a cyclic group which may have substituent(s); X is a spacer having 1 to 8 atoms in its main chain, etc.; Y is a spacer having 1 to 10 atoms in its main chain, etc.; n is 0 or 1, wherein when n is 0, m is 1 and R1 is a hydrogen atom or a substituent, and wherein when n is 1, m is 0 or an integer of 1 to 7 and R1 is a substituent, and wherein m is 2 or more, R1s are the same or different.
摘要翻译: 具有与S1P受体(特别是EDG-6,优选EDG-1和EDG-6)结合的能力的化合物,例如本发明的式(I)表示的化合物,其盐,其溶剂合物 或其前药可用于预防和/或治疗移植排斥反应,移植物抗宿主病,自身免疫性疾病,过敏性疾病等。 其中环A是环状基团; 环B是可以具有取代基的环状基团; X是其主链中具有1至8个原子的间隔物等; Y是其主链中具有1至10个原子的间隔物等; n为0或1,其中当n为0时,m为1,R 1为氢原子或取代基,n为1时,m为0或1〜7的整数,R 1为取代基,其中, m为2以上,R 1相同或不同。
-
公开(公告)号:US20110015425A1
公开(公告)日:2011-01-20
申请号:US12933131
申请日:2009-03-17
申请人: Gottfried Sedelmeier
发明人: Gottfried Sedelmeier
IPC分类号: C07C229/36 , C07C209/70 , C07C227/16 , C07C215/34
CPC分类号: C07C213/08 , C07C215/28 , C07C215/30 , C07C231/12 , C07C233/22 , C07C233/51 , Y02P20/55
摘要: The present invention relates to improved processes for the production of 2-amino-2-[2-(4-C2-20-alkyl-phenyl)ethyl]propane-1,3-diols, and to compounds for use therein.
摘要翻译: 本发明涉及2-氨基-2- [2-(4-(C 2 -C 20 - 烷基 - 苯基)乙基]丙烷-1,3-二醇的制备方法和用于其中的化合物。
-
公开(公告)号:US20110003842A1
公开(公告)日:2011-01-06
申请号:US12865725
申请日:2009-01-30
申请人: Yusuke Tanigawara , Mitsuhiro Watanabe , Eri Arita , Akito Nishimuta , Yasuko Yamayoshi , Takeshi Matsuzaki , Shinji Sugimoto
发明人: Yusuke Tanigawara , Mitsuhiro Watanabe , Eri Arita , Akito Nishimuta , Yasuko Yamayoshi , Takeshi Matsuzaki , Shinji Sugimoto
IPC分类号: A61K31/4375 , C07C229/36 , C07C229/08 , G01N33/68 , A61P35/00
CPC分类号: A61K31/4745 , A61K45/06 , G01N33/5011 , G01N33/6812 , G01N2800/52 , Y10S436/813 , A61K2300/00
摘要: Provided are a marker for determining sensitivity to an anticancer agent capable of distinguishing a therapeutic response of an individual patient and a novel means for a cancer therapy using the marker. The marker for determining sensitivity to an anticancer agent contains a substance in a metabolic pathway in which L-phenylalanine and/or N,N-dimethyl glycine are/is involved.
摘要翻译: 提供了用于确定对能够区分各个患者的治疗反应的抗癌剂的敏感性的标记和使用该标记的癌症治疗的新手段。 用于确定对抗癌剂的敏感性的标记物含有涉及L-苯丙氨酸和/或N,N-二甲基甘氨酸的代谢途径中的物质。
-
46.
公开(公告)号:US20100298538A1
公开(公告)日:2010-11-25
申请号:US12743470
申请日:2008-11-19
IPC分类号: C07C229/36 , C07C271/08 , C07K1/06
CPC分类号: C07C271/22 , C07B53/00 , C07B2200/07 , C07C67/31 , C07C227/32 , C07C229/36 , C07C247/12 , C07C271/34 , C07C2603/18 , C07D203/02 , C07D203/06 , C07K1/04 , C07K5/0812 , C07C69/732
摘要: The invention relates to a process for the stereoselective preparation of amino acid derivatives, comprising a hydrogenation reaction of the compound of formula (III), alternatively its enantiomer, wherein R is (C1-C8)-alkyl; followed by a hydrolysis reaction to obtain L-mesityl alanine, alternatively its enantiomer D-mesityl alanine and, optionally, subjecting said compound to an amino group protection reaction, particularly as Fmoc. It also comprises Fmoc-L- or Fmoc-D-mesityl alanine as products per se, useful as intermediates in preparing peptides or peptide analogs with therapeutic or biological activity.
摘要翻译: 本发明涉及一种用于立体选择性制备氨基酸衍生物的方法,包括式(III)化合物或其对映异构体的氢化反应,其中R是(C 1 -C 8) - 烷基; 然后进行水解反应以获得L-均三甲基丙氨酸,或者其对映体D-均三甲基丙氨酸,以及任选地使所述化合物进行氨基保护反应,特别是作为Fmoc。 它还包含Fmoc-L-或Fmoc-D-mesityl丙氨酸作为产品本身,可用作制备具有治疗或生物活性的肽或肽类似物的中间体。
-
公开(公告)号:US20100286227A1
公开(公告)日:2010-11-11
申请号:US12811115
申请日:2008-01-28
申请人: Chia-Chin Sheu , Tun-Tschu Chang , Masao Hattori
发明人: Chia-Chin Sheu , Tun-Tschu Chang , Masao Hattori
IPC分类号: A61K31/4015 , C07D307/60 , A61K31/366 , A61P31/14 , C07D207/452 , C07D207/46 , C07C59/64 , A61K31/194 , C07C69/734 , A61K31/225 , C07C229/36 , A61K31/198 , C07D207/28
CPC分类号: C07C235/34 , C07D207/444 , C07D207/46 , C07D207/50 , C07D307/60
摘要: The present invention relates to compounds from mycelium of Antrodia cinnamomea. The present invention also relates to a composition and a method for treating or prophylaxis of hepatitis C virus (HCV) infection.
摘要翻译: 本发明涉及来自肉桂樟脑菌菌丝体的化合物。 本发明还涉及治疗或预防丙型肝炎病毒(HCV)感染的组合物和方法。
-
公开(公告)号:US20100280108A1
公开(公告)日:2010-11-04
申请号:US12746966
申请日:2008-12-19
申请人: Alberto Rodriguez Vicente , Maria Garranzo García-Ibarrola , Carmen Murcia Pérez , Francisco Sánchez Sancho , Maria del Carmen Cuevas Marchante , Cristina Mateo Urbano , Isabel Digón Juárez
发明人: Alberto Rodriguez Vicente , Maria Garranzo García-Ibarrola , Carmen Murcia Pérez , Francisco Sánchez Sancho , Maria del Carmen Cuevas Marchante , Cristina Mateo Urbano , Isabel Digón Juárez
IPC分类号: A61K31/216 , C07C237/52 , C07C271/12 , C07C229/36 , A61K31/165 , A61P35/00
CPC分类号: A61K31/695 , A61K31/351 , A61K31/366 , C07D309/10 , C07D309/30 , C07D309/32 , C07F7/1804 , Y02P20/55
摘要: A compound of general formula (I) wherein, R11, R12, R13, R14, R15, W, Y, R1, R2, R3, R4, R5, and R6 take various meanings for use in the treatment of cancer.
摘要翻译: 通式(I)的化合物,其中R11,R12,R13,R14,R15,W,Y,R1,R2,R3,R4,R5和R6具有用于治疗癌症的各种含义。
-
公开(公告)号:US20100172916A1
公开(公告)日:2010-07-08
申请号:US12614530
申请日:2009-11-09
申请人: Thomas G. Gant , Craig Hodulik , Soon Woo
发明人: Thomas G. Gant , Craig Hodulik , Soon Woo
IPC分类号: A61K31/7084 , A61K31/122 , A61K38/44 , A61K33/26 , A61K36/48 , A61K31/714 , A61K31/675 , A61K31/66 , A61K31/55 , A61K31/551 , A61K31/5375 , A61K31/519 , A61K31/4985 , A61K31/525 , A61K31/506 , A61K31/515 , A61K31/435 , A61K31/473 , A61K31/48 , A61K31/437 , A61K31/4545 , A61K31/4415 , A61K31/455 , A61K31/4409 , A61K31/428 , A61K31/421 , A61K31/4045 , A61K31/381 , A61K31/355 , A61K31/375 , A61K31/197 , A61K31/165 , A61K31/135 , C07C229/36 , C07C211/03 , A61P25/00 , A61P3/00 , A61P3/04 , A61P25/16 , A61P25/24 , A61P25/28 , A61P25/22 , A61P25/30 , A61P31/18 , A61K39/395
CPC分类号: C07C229/36 , A61K31/135 , A61K31/195 , A61K31/216 , A61K45/06 , C07C215/52 , A61K2300/00
摘要: The present invention relates to new substituted hydroxyphenylamine based modulators of hormone and/or pigment levels, pharmaceutical compositions thereof, and methods of use thereof.
摘要翻译: 本发明涉及新的基于羟基苯基胺的激素和/或颜料水平的调节剂,其药物组合物及其使用方法。
-
50.
公开(公告)号:US20090247470A1
公开(公告)日:2009-10-01
申请号:US12056506
申请日:2008-03-27
申请人: Guangyi Liang , Bixue Xu , Changxiao Liu , Zhengming Huang , Peixue Cao , Zegui Cai , Yuming Liu
发明人: Guangyi Liang , Bixue Xu , Changxiao Liu , Zhengming Huang , Peixue Cao , Zegui Cai , Yuming Liu
IPC分类号: A61K38/05 , C07C229/36 , C07D265/30 , A61P31/12
CPC分类号: C07D295/155 , C07C231/02 , C07C233/76 , C07C235/32 , C07C237/32 , C07D213/81
摘要: Disclosed are a compound of formula I, stereoisomers, pharmaceutically acceptable salts or hydrates thereof, a pharmaceutical composition comprising the smae, a process for preparing the same and use thereof. The compound may also be used to prepare a medicament to treat viral infections, especially to prepare a medicament to treat hepatitis B virus and human immunodeficiency virus with little toxic side effects.
摘要翻译: 公开了式I的化合物,其立体异构体,药学上可接受的盐或水合物,包含该药物的药物组合物,其制备方法及其用途。 该化合物也可用于制备治疗病毒感染的药物,特别是制备药物以治疗乙型肝炎病毒和少量毒副作用的人类免疫缺陷病毒。
-
-
-
-
-
-
-
-
-